Latest Ratios: P/E Ratio -10.7x · EV/EBITDA N/A · ROE -38.9%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.4B | $3.2B | $1.6B | $7.7B | $7.8B | $18.8B | $8.2B | $3.1B | $1.8B | $672M |
| Enterprise Value | $1.5B | $1.6B | $3.7B | $1.9B | $8.1B | $8.1B | $19.0B | $8.2B | $3.1B | $1.8B | $668M |
| P/E Ratio → | -10.69 | — | — | — | — | — | 961.33 | — | — | — | — |
| P/S Ratio | 1.78 | 2.20 | 5.31 | 3.12 | 14.27 | 14.51 | 38.11 | 23.32 | 12.39 | 10.10 | 8.10 |
| P/B Ratio | 3.65 | 4.23 | 8.92 | 4.38 | 17.40 | 18.92 | 39.54 | 37.62 | 27.39 | 15.75 | 4.72 |
| P/FCF | — | — | — | — | 814.09 | 132.55 | 223.81 | 507.85 | — | — | — |
| P/OCF | — | — | — | — | 249.35 | 93.84 | 190.02 | 307.82 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.48 | 6.17 | 3.82 | 15.15 | 15.21 | 38.52 | 23.29 | 12.43 | 10.21 | 8.06 |
| EV / EBITDA | — | — | — | — | — | — | 481.52 | 1084.41 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 533.70 | 1620.39 | — | — | — |
| EV / FCF | — | — | — | — | 863.82 | 138.91 | 226.24 | 507.16 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.5% | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% | 74.8% | 67.7% | 68.6% | 44.2% |
| Operating Margin | -23.5% | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% | 6.1% | -0.3% | -13.6% | -22.2% | -139.1% |
| Net Profit Margin | -20.8% | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% | -2.1% | -25.6% | -34.8% | -159.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -38.9% | -38.9% | -46.7% | -51.5% | -21.7% | -13.2% | 5.7% | -4.4% | -56.3% | -48.2% | -67.1% |
| ROA | -13.3% | -13.3% | -14.1% | -17.7% | -7.9% | -5.3% | 2.6% | -1.8% | -21.0% | -22.5% | -44.7% |
| ROIC | -16.4% | -16.4% | -16.0% | -21.5% | -7.9% | -4.5% | 5.1% | -0.4% | -19.9% | -21.8% | -59.0% |
| ROCE | -28.9% | -28.9% | -23.5% | -23.3% | -8.8% | -4.6% | 4.6% | -0.3% | -13.7% | -17.1% | -44.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | 1.90 | 1.64 | 1.32 | 1.42 | 0.95 | 0.77 | 1.33 | 0.86 | 0.68 |
| Debt / EBITDA | — | — | — | — | — | — | 11.39 | 22.29 | — | — | — |
| Net Debt / Equity | — | 0.55 | 1.44 | 0.98 | 1.06 | 0.91 | 0.43 | -0.05 | 0.08 | 0.17 | -0.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | 5.17 | -1.49 | — | — | — |
| Debt / FCF | — | — | — | — | 49.73 | 6.35 | 2.43 | -0.70 | — | — | — |
| Interest Coverage | — | — | -10.36 | -38.41 | -9.68 | -5.50 | 1.98 | 0.34 | -1.92 | -3.15 | -16.55 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.90 | 2.90 | 1.46 | 5.78 | 7.00 | 7.53 | 8.80 | 5.10 | 4.98 | 4.88 | 7.10 |
| Quick Ratio | 2.71 | 2.71 | 1.42 | 5.56 | 6.82 | 7.36 | 8.56 | 4.82 | 4.63 | 4.44 | 6.41 |
| Cash Ratio | 2.05 | 2.05 | 1.27 | 5.08 | 6.11 | 6.58 | 7.52 | 3.80 | 3.81 | 3.65 | 5.96 |
| Asset Turnover | — | 0.81 | 0.49 | 0.44 | 0.45 | 0.47 | 0.47 | 0.73 | 0.73 | 0.67 | 0.29 |
| Inventory Turnover | 4.06 | 4.06 | 3.91 | 3.36 | 3.91 | 4.70 | 3.88 | 3.74 | 3.55 | 2.52 | 1.81 |
| Days Sales Outstanding | — | 64.24 | 61.56 | 55.26 | 71.95 | 66.45 | 74.18 | 66.45 | 53.74 | 60.96 | 27.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.1% | — | — | — | — |
| FCF Yield | — | — | — | — | 0.1% | 0.8% | 0.4% | 0.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $111M | $108M | $106M | $105M | $103M | $109M | $97M | $92M | $89M | $86M |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVCR stock.
Novocure Ltd's current P/E ratio is -10.7x. This places it at the 50th percentile of its historical range.
Novocure Ltd's return on equity (ROE) is -38.9%. The historical average is -39.3%.
Based on historical data, Novocure Ltd is trading at a P/E of -10.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Novocure Ltd has 74.5% gross margin and -23.5% operating margin.
Key Metrics
Top Statement Risk
Persistent operating losses and refinancing dependence
Metrics are mathematically derived from official filings.
Premium Multiples Against Persistent Losses
Based on NVCR's reported figures, the price-to-sales multiple of 2.35 and price-to-book of 4.35 sit above typical medtech levels, while the negative trailing P/E of -10.89 leaves earnings-based valuation unusable and shifts the case toward revenue growth durability.
With no positive trailing earnings, the market appears to be pricing NVCR on revenue trajectory and the expected commercial ramp of TTFields rather than current profitability. A price-to-book of 4.35 against accumulated deficits of roughly -$1.4B suggests the market is valuing pipeline and intangible optionality well beyond tangible equity. Investors should monitor whether the 15.7% year-over-year revenue growth in the latest quarter can sustain a multiple that current earnings do not support.
Gross Margin Strength Obscured by Operating Losses
According to reported financial statements, NVCR's gross margin held near 77.0% in 3Q26 across a band of 73.2% to 79.2%, yet operating margin of -3.2% and net margin of -5.4% indicate the high-margin disposable model has not yet absorbed the R&D and SG&A base.
The stability of gross margin points to intact unit economics on the disposable transducer array model, the strongest structural feature in the ratio set. The gap between gross and operating margin reflects a fixed cost base sized for clinical expansion rather than current GBM revenue. Operating margin improved from -39.3% in 4Q24 to -3.2% in 3Q26, which may indicate growing operating leverage, but the absence of any positive operating quarter means earning power remains unproven.
Returns Recovering From Deep Negative Levels
Based on reported figures, ROIC improved from -10.2% in 1Q26 to -1.0% in 3Q26 and ROE moved from -21.2% to -3.0% over the same span, showing directional recovery from deeply negative returns but no positive capital compounding yet.
The trajectory suggests returns are converging toward breakeven as operating losses narrow rather than decaying further. Because ROE and ROIC remain negative, the company is still consuming rather than compounding invested capital. The improvement appears driven primarily by margin recovery rather than asset efficiency, since asset turnover has stayed in a tight range near 0.22 to 0.24, so sustained positive returns would depend on continued margin expansion.
Deleveraging Reduces Refinancing Pressure
As reported in financial statements, NVCR's debt-to-equity ratio fell from 2.34 in 3Q25 to 0.66 in 3Q26 as total debt declined to about $231.6M, though interest coverage remains negative and cannot yet confirm that debt service has become comfortable.
The sharp reduction in debt lowers the balance sheet risk that dominated the prior year, and the current debt-to-equity of 0.66 is more manageable than earlier readings. However, negative interest coverage means earnings do not currently cover interest expense, so the comfort of the leverage position depends on the cash balance rather than operating income. The deleveraging also coincided with cash that did not rise commensurately, which warrants further investigation into how repayment was financed.
Deleveraging May Mask Cash Dependence
Based on reported figures, the debt-to-EBITDA ratio is unavailable because EBITDA is negative, so the most commonly cited leverage metric cannot be used here and investors may instead rely on a misleading headline debt-to-equity improvement.
Debt-to-EBITDA is frequently applied to medtech issuers to gauge repayment capacity, but with operating income negative it yields no meaningful reading and obscures the true dependence on cash reserves and external funding. The headline fall in debt-to-equity from 2.34 to 0.66 may suggest durable balance sheet repair, yet it does not demonstrate that repayment came from operating cash generation. A more useful adjustment would be to track net cash burn against cash on hand and the timing of any refinancing, which warrants monitoring given the unexplained cash gap.